{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:56:40Z","timestamp":1795046200450,"version":"4.10.2"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    ADAR1 is an RNA editing enzyme which prevents autoimmunity by blocking interferon responses triggered by cytosolic RNA sensors, and is a potential target in immuno-oncology. However, predictive biomarkers for ADAR1 inhibition are lacking. Using multiple in vitro and in vivo systems, we show that\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    and\n                    <jats:italic>ADAR1<\/jats:italic>\n                    are synthetically lethal, and that ADAR1 activity is upregulated in\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    -mutant cancers. ADAR1 depletion in\n                    <jats:italic>BRCA1<\/jats:italic>\n                    -mutant cells causes an increase in R-loops and consequently, an upregulation of cytosolic nucleic acid sensing pattern recognition receptors (PRR), events which are associated with a tumor cell-autonomous type I interferon and integrated stress response. This ultimately causes autocrine interferon poisoning. Consistent with a key role of R-loops in this process, exogenous RNase H1 expression reverses the synthetic lethality. Pharmacological suppression of cell-autonomous interferon responses or transcriptional silencing of cytosolic nucleic acid sensing PRR are also sufficient to abrogate\n                    <jats:italic>ADAR1<\/jats:italic>\n                    dependency in\n                    <jats:italic>BRCA1<\/jats:italic>\n                    -mutant cells, in line with autocrine interferon poisoning playing a central part in this synthetic lethality. Our findings provide a preclinical rationale for assessing ADAR1-targeting agents in\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    -mutant cancers, and introduces a conceptually novel approach to synthetic lethal treatments, which exploits tumor cell-intrinsic cytosolic immunity as a targetable vulnerability of cancer cells.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-62309-5","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:11:06Z","timestamp":1753819866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1\/2-mutant cancers"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-3060","authenticated-orcid":false,"given":"Roman M.","family":"Chabanon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-9974","authenticated-orcid":false,"given":"Liudmila","family":"Shcherbakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-8536","authenticated-orcid":false,"given":"Magali","family":"Lacroix-Triki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-8904","authenticated-orcid":false,"given":"Marine","family":"Aglave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-4085","authenticated-orcid":false,"given":"Jean","family":"Zeghondy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3643-2488","authenticated-orcid":false,"given":"Victor","family":"Kriaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6996-2246","authenticated-orcid":false,"given":"Antoine","family":"Goug\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Edmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4298-7272","authenticated-orcid":false,"given":"Dragomir B.","family":"Krastev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Brough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-3857","authenticated-orcid":false,"given":"Stephen J.","family":"Pettitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Thomas-Bonafos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6860-2401","authenticated-orcid":false,"given":"Robert","family":"Samstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6352-101X","authenticated-orcid":false,"given":"Marc","family":"Deloger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-2901","authenticated-orcid":false,"given":"Andrew NJ","family":"Tutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5793-3539","authenticated-orcid":false,"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1739","authenticated-orcid":false,"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-9165","authenticated-orcid":false,"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4267-4743","authenticated-orcid":false,"given":"Marcel","family":"Tawk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-3627","authenticated-orcid":false,"given":"Cindy","family":"Degerny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4063-0771","authenticated-orcid":false,"given":"Yea-Lih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5891-0822","authenticated-orcid":false,"given":"Philippe","family":"Pasero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-0515","authenticated-orcid":false,"given":"Christopher J.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-1857","authenticated-orcid":false,"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"62309_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41576-018-0006-1","volume":"19","author":"E Eisenberg","year":"2018","unstructured":"Eisenberg, E. & Levanon, E. Y. A-to-I RNA editing - immune protector and transcriptome diversifier. Nat. Rev. Genet. 19, 473\u2013490 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"62309_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrm.2015.4","volume":"17","author":"K Nishikura","year":"2016","unstructured":"Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat. Rev. Mol. Cell Biol. 17, 83\u201396 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"62309_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41577-023-00940-3","volume":"24","author":"R de Reuver","year":"2024","unstructured":"de Reuver, R. & Maelfait, J. Novel insights into double-stranded RNA-mediated immunopathology. Nat. Rev. Immunol. 24, 235\u2013249 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"62309_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21921-x","volume":"12","author":"Y Shiromoto","year":"2021","unstructured":"Shiromoto, Y., Sakurai, M., Minakuchi, M., Ariyoshi, K. & Nishikura, K. ADAR1 RNA editing enzyme regulates R-loop formation and genome stability at telomeres in cancer cells. Nat. Commun. 12, 1654 (2021).","journal-title":"Nat. Commun."},{"key":"62309_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25790-2","volume":"12","author":"S Jimeno","year":"2021","unstructured":"Jimeno, S. et al. ADAR-mediated RNA editing of DNA:RNA hybrids is required for DNA double strand break repair. Nat. Commun. 12, 5512 (2021).","journal-title":"Nat. Commun."},{"key":"62309_CR6","doi-asserted-by":"publisher","first-page":"11668","DOI":"10.1093\/nar\/gkad839","volume":"51","author":"B Zhang","year":"2023","unstructured":"Zhang, B. et al. ADAR1 links R-loop homeostasis to ATR activation in replication stress response. Nucleic Acids Res. 51, 11668\u201311687 (2023).","journal-title":"Nucleic Acids Res"},{"key":"62309_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","volume":"21","author":"RM Chabanon","year":"2021","unstructured":"Chabanon, R. M. et al. Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat. Rev. Cancer 21, 701\u2013717 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"62309_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","volume":"619","author":"AVR Kornepati","year":"2023","unstructured":"Kornepati, A. V. R., Rogers, C. M., Sung, P. & Curiel, T. J. The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature 619, 475\u2013486 (2023).","journal-title":"Nature"},{"key":"62309_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"62309_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","volume":"565","author":"JJ Ishizuka","year":"2019","unstructured":"Ishizuka, J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43\u201348 (2019).","journal-title":"Nature"},{"key":"62309_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","volume":"25","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat. Med. 25, 95\u2013102 (2019).","journal-title":"Nat. Med."},{"key":"62309_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07824-4","volume":"9","author":"HS Gannon","year":"2018","unstructured":"Gannon, H. S. et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat. Commun. 9, 5450 (2018).","journal-title":"Nat. Commun."},{"key":"62309_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41388-020-01515-5","volume":"40","author":"C-P Kung","year":"2021","unstructured":"Kung, C.-P. et al. Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene 40, 189\u2013202 (2021).","journal-title":"Oncogene"},{"key":"62309_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41586-020-2844-1","volume":"588","author":"P Mehdipour","year":"2020","unstructured":"Mehdipour, P. et al. Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency. Nature 588, 169\u2013173 (2020).","journal-title":"Nature"},{"key":"62309_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41588-021-00859-2","volume":"53","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nat. Genet. 53, 881\u2013894 (2021).","journal-title":"Nat. Genet."},{"key":"62309_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.trecan.2018.08.003","volume":"4","author":"CJ Ryan","year":"2018","unstructured":"Ryan, C. J., Bajrami, I. & Lord, C. J. Synthetic Lethality and Cancer - Penetrance as the Major Barrier. Trends Cancer 4, 671\u2013683 (2018).","journal-title":"Trends Cancer"},{"key":"62309_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"62309_CR18","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","volume":"25","author":"L Ding","year":"2018","unstructured":"Ding, L. et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 25, 2972\u20132980 (2018).","journal-title":"Cell Rep."},{"key":"62309_CR19","doi-asserted-by":"publisher","first-page":"djw199","DOI":"10.1093\/jnci\/djw199","volume":"109","author":"EE Parkes","year":"2017","unstructured":"Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J. Natl. Cancer Inst. 109, djw199 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"62309_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1172\/JCI123319","volume":"129","author":"RM Chabanon","year":"2019","unstructured":"Chabanon, R. M. et al. PARP inhibition enhances tumor cell\u2013intrinsic immunity in ERCC1-deficient non\u2013small cell lung cancer. J. Clin. Invest. 129, 1211\u20131228 (2019).","journal-title":"J. Clin. Invest."},{"key":"62309_CR21","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1038\/s41467-019-11048-5","volume":"10","author":"T Reisl\u00e4nder","year":"2019","unstructured":"Reisl\u00e4nder, T. et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat. Commun. 10, 3143 (2019).","journal-title":"Nat. Commun."},{"key":"62309_CR22","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1158\/1535-7163.MCT-17-0098","volume":"16","author":"A Dr\u00e9an","year":"2017","unstructured":"Dr\u00e9an, A. et al. Modeling therapy resistance in BRCA1\/2-mutant cancers. Mol. Cancer Ther. 16, 2022\u20132034 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"62309_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.molcel.2019.09.024","volume":"77","author":"E Callen","year":"2020","unstructured":"Callen, E. et al. 53BP1 enforces distinct pre- and post-resection blocks on homologous recombination. Mol. Cell 77, 26\u201338.e7 (2020).","journal-title":"Mol. Cell"},{"key":"62309_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","volume":"560","author":"SM Noordermeer","year":"2018","unstructured":"Noordermeer, S. M. et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature 560, 117\u2013121 (2018).","journal-title":"Nature"},{"key":"62309_CR25","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","volume":"1","author":"RM Samstein","year":"2021","unstructured":"Samstein, R. M. et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat. Cancer 1, 1188\u20131203 (2021).","journal-title":"Nat. Cancer"},{"key":"62309_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17119-1","volume":"7","author":"JB Walton","year":"2017","unstructured":"Walton, J. B. et al. CRISPR\/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Sci. Rep. 7, 16827 (2017).","journal-title":"Sci. Rep."},{"key":"62309_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23463-8","volume":"12","author":"D Zatreanu","year":"2021","unstructured":"Zatreanu, D. et al. Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat. Commun. 12, 3636 (2021).","journal-title":"Nat. Commun."},{"key":"62309_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2017.12.038","volume":"172","author":"H Chung","year":"2018","unstructured":"Chung, H. et al. Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell 172, 811\u2013824.e14 (2018).","journal-title":"Cell"},{"key":"62309_CR29","doi-asserted-by":"publisher","first-page":"e2021757118","DOI":"10.1073\/pnas.2021757118","volume":"118","author":"T Sun","year":"2021","unstructured":"Sun, T. et al. Decoupling expression and editing preferences of ADAR1 p150 and p110 isoforms. Proc. Natl. Acad. Sci. USA 118, e2021757118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62309_CR30","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1016\/j.molcel.2023.09.018","volume":"83","author":"S-B Hu","year":"2023","unstructured":"Hu, S.B. et al. ADAR1p150 prevents MDA5 and PKR activation via distinct mechanisms to avert fatal autoinflammation. Mol. Cell 83, 3869\u20133884.e7 (2023).","journal-title":"Mol. Cell"},{"key":"62309_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.2414","volume":"44","author":"GI Rice","year":"2012","unstructured":"Rice, G. I. et al. Mutations in ADAR1 cause aicardi-gouti\u00e8res syndrome associated with a type I interferon signature. Nat. Genet. 44, 1243\u20131248 (2012).","journal-title":"Nat. Genet."},{"key":"62309_CR32","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/386804a0","volume":"386","author":"SK Sharan","year":"1997","unstructured":"Sharan, S. K. et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804\u2013810 (1997).","journal-title":"Nature"},{"key":"62309_CR33","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature12111","volume":"496","author":"K Howe","year":"2013","unstructured":"Howe, K. et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 496, 498\u2013503 (2013).","journal-title":"Nature"},{"key":"62309_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16725-3","volume":"7","author":"J Vierstraete","year":"2017","unstructured":"Vierstraete, J. et al. Accurate quantification of homologous recombination in zebrafish: brca2 deficiency as a paradigm. Sci. Rep. 7, 16518 (2017).","journal-title":"Sci. Rep."},{"key":"62309_CR35","doi-asserted-by":"publisher","first-page":"103023","DOI":"10.1016\/j.dnarep.2020.103023","volume":"97","author":"J Vierstraete","year":"2021","unstructured":"Vierstraete, J., Fieuws, C., Willaert, A., Vral, A. & Claes, K. B. M. Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy. DNA Repair 97, 103023 (2021).","journal-title":"DNA Repair"},{"key":"62309_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33260-6","volume":"13","author":"K Niescierowicz","year":"2022","unstructured":"Niescierowicz, K. et al. Adar-mediated A-to-I editing is required for embryonic patterning and innate immune response regulation in zebrafish. Nat. Commun. 13, 5520 (2022).","journal-title":"Nat. Commun."},{"key":"62309_CR37","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1093\/nar\/gkab247","volume":"49","author":"I Buchumenski","year":"2021","unstructured":"Buchumenski, I. et al. Systematic identification of A-to-I RNA editing in zebrafish development and adult organs. Nucleic Acids Res. 49, 4325\u20134337 (2021).","journal-title":"Nucleic Acids Res"},{"key":"62309_CR38","first-page":"2819","volume":"194","author":"PR Kasher","year":"2015","unstructured":"Kasher, P. R. et al. Characterization of samhd1 morphant zebrafish recapitulates features of the human type I interferonopathy Aicardi-Gouti\u00e8res syndrome. J. Immunol. Baltim. Md 1950 194, 2819\u20132825 (2015).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"62309_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/zeb.2008.0555","volume":"6","author":"BR Bill","year":"2009","unstructured":"Bill, B. R., Petzold, A. M., Clark, K. J., Schimmenti, L. A. & Ekker, S. C. A primer for morpholino use in zebrafish. Zebrafish 6, 69\u201377 (2009).","journal-title":"Zebrafish"},{"key":"62309_CR40","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41588-025-02108-2","volume":"57","author":"S Haider","year":"2025","unstructured":"Haider, S. et al. The transcriptomic architecture of common cancers reflects synthetic lethal interactions. Nat. Genet. 57, 522\u2013529 (2025).","journal-title":"Nat. Genet."},{"key":"62309_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.celrep.2015.08.080","volume":"13","author":"N Paz-Yaacov","year":"2015","unstructured":"Paz-Yaacov, N. et al. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 13, 267\u2013276 (2015).","journal-title":"Cell Rep."},{"key":"62309_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.celrep.2015.09.032","volume":"13","author":"D Fumagalli","year":"2015","unstructured":"Fumagalli, D. et al. Principles governing A-to-I RNA editing in the breast cancer transcriptome. Cell Rep. 13, 277\u2013289 (2015).","journal-title":"Cell Rep."},{"key":"62309_CR43","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41592-019-0610-9","volume":"16","author":"SH Roth","year":"2019","unstructured":"Roth, S. H., Levanon, E. Y. & Eisenberg, E. Genome-wide quantification of ADAR adenosine-to-inosine RNA editing activity. Nat. Methods 16, 1131\u20131138 (2019).","journal-title":"Nat. Methods"},{"key":"62309_CR44","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/bioinformatics\/btx473","volume":"33","author":"F Zhang","year":"2017","unstructured":"Zhang, F., Lu, Y., Yan, S., Xing, Q. & Tian, W. SPRINT: an SNP-free toolkit for identifying RNA editing sites. Bioinforma. Oxf. Engl. 33, 3538\u20133548 (2017).","journal-title":"Bioinforma. Oxf. Engl."},{"key":"62309_CR45","unstructured":"Bigot, L. et al. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer. Eur. Urol. Oncol. S2588-9311, 00226\u20132 (2023)."},{"key":"62309_CR46","first-page":"73","volume":"5","author":"AA Sch\u00e4ffer","year":"2024","unstructured":"Sch\u00e4ffer, A. A., Chung, Y., Kammula, A. V., Ruppin, E. & Lee, J. S. A systematic analysis of the landscape of synthetic lethality-driven precision oncology. Med N. Y. N. 5, 73\u201389.e9 (2024).","journal-title":"Med N. Y. N."},{"key":"62309_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N. & Tarsounas, M. Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer 23, 78\u201394 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"62309_CR48","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41586-022-04767-1","volume":"606","author":"S Tang","year":"2022","unstructured":"Tang, S., Stokasimov, E., Cui, Y. & Pellman, D. Breakage of cytoplasmic chromosomes by pathological DNA base excision repair. Nature 606, 930\u2013936 (2022).","journal-title":"Nature"},{"key":"62309_CR49","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/s41588-021-00867-2","volume":"53","author":"A Bayona-Feliu","year":"2021","unstructured":"Bayona-Feliu, A., Barroso, S., Mu\u00f1oz, S. & Aguilera, A. The SWI\/SNF chromatin remodeling complex helps resolve R-loop-mediated transcription-replication conflicts. Nat. Genet. 53, 1050\u20131063 (2021).","journal-title":"Nat. Genet."},{"key":"62309_CR50","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri2314","volume":"8","author":"AJ Sadler","year":"2008","unstructured":"Sadler, A. J. & Williams, B. R. G. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8, 559\u2013568 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"62309_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nri.2015.8","volume":"16","author":"X Cao","year":"2016","unstructured":"Cao, X. Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat. Rev. Immunol. 16, 35\u201350 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"62309_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03782-z","volume":"9","author":"S Ding","year":"2018","unstructured":"Ding, S. et al. STAG2 deficiency induces interferon responses via cGAS-STING pathway and restricts virus infection. Nat. Commun. 9, 1485 (2018).","journal-title":"Nat. Commun."},{"key":"62309_CR53","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois, D. et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 162, 961\u2013973 (2015).","journal-title":"Cell"},{"key":"62309_CR54","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.immuni.2021.07.001","volume":"54","author":"M Maurano","year":"2021","unstructured":"Maurano, M. et al. Protein kinase R and the integrated stress response drive immunopathology caused by mutations in the RNA deaminase ADAR1. Immunity 54, 1948\u20131960.e5 (2021).","journal-title":"Immunity"},{"key":"62309_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41586-022-05545-9","volume":"613","author":"MP Crossley","year":"2023","unstructured":"Crossley, M. P. et al. R-loop-derived cytoplasmic RNA-DNA hybrids activate an immune response. Nature 613, 187\u2013194 (2023).","journal-title":"Nature"},{"key":"62309_CR56","doi-asserted-by":"publisher","first-page":"831","DOI":"10.15252\/embj.201593339","volume":"35","author":"KJ Mackenzie","year":"2016","unstructured":"Mackenzie, K. J. et al. Ribonuclease H2 mutations induce a cGAS\/STING-dependent innate immune response. EMBO J. 35, 831\u2013844 (2016).","journal-title":"EMBO J."},{"key":"62309_CR57","doi-asserted-by":"publisher","first-page":"eabj5769","DOI":"10.1126\/sciadv.abj5769","volume":"7","author":"O Chatzidoukaki","year":"2021","unstructured":"Chatzidoukaki, O. et al. R-loops trigger the release of cytoplasmic ssDNAs leading to chronic inflammation upon DNA damage. Sci. Adv. 7, eabj5769 (2021).","journal-title":"Sci. Adv."},{"key":"62309_CR58","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00018-024-05380-3","volume":"81","author":"L Zannini","year":"2024","unstructured":"Zannini, L., Cardano, M., Liberi, G. & Buscemi, G. R-loops and impaired autophagy trigger cGAS-dependent inflammation via micronuclei formation in Senataxin-deficient cells. Cell. Mol. Life Sci. CMLS 81, 339 (2024).","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"62309_CR59","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2159-8290.CD-23-0486","volume":"14","author":"T Murayama","year":"2024","unstructured":"Murayama, T. et al. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in small cell lung cancer. Cancer Discov. 14, 468\u2013491 (2024).","journal-title":"Cancer Discov."},{"key":"62309_CR60","first-page":"00451","volume":"S0092-8674","author":"MB Maxwell","year":"2024","unstructured":"Maxwell, M. B. et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell S0092-8674, 00451\u201300453 (2024).","journal-title":"Cell"},{"key":"62309_CR61","doi-asserted-by":"publisher","first-page":"e20220829","DOI":"10.1084\/jem.20220829","volume":"220","author":"T Schumann","year":"2023","unstructured":"Schumann, T. et al. Deficiency for SAMHD1 activates MDA5 in a cGAS\/STING-dependent manner. J. Exp. Med. 220, e20220829 (2023).","journal-title":"J. Exp. Med."},{"key":"62309_CR62","doi-asserted-by":"publisher","first-page":"e20211121","DOI":"10.1084\/jem.20211121","volume":"219","author":"AMS Giordano","year":"2022","unstructured":"Giordano, A. M. S. et al. DNA damage contributes to neurotoxic inflammation in Aicardi-Gouti\u00e8res syndrome astrocytes. J. Exp. Med. 219, e20211121 (2022).","journal-title":"J. Exp. Med."},{"key":"62309_CR63","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1091\/mbc.12.7.1911","volume":"12","author":"CR Eckmann","year":"2001","unstructured":"Eckmann, C. R., Neunteufl, A., Pfaffstetter, L. & Jantsch, M. F. The human but not the Xenopus RNA-editing enzyme ADAR1 has an atypical nuclear localization signal and displays the characteristics of a shuttling protein. Mol. Biol. Cell 12, 1911\u20131924 (2001).","journal-title":"Mol. Biol. Cell"},{"key":"62309_CR64","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1091\/mbc.e02-03-0161","volume":"13","author":"A Strehblow","year":"2002","unstructured":"Strehblow, A., Hallegger, M. & Jantsch, M. F. Nucleocytoplasmic distribution of human RNA-editing enzyme ADAR1 is modulated by double-stranded RNA-binding domains, a leucine-rich export signal, and a putative dimerization domain. Mol. Biol. Cell 13, 3822\u20133835 (2002).","journal-title":"Mol. Biol. Cell"},{"key":"62309_CR65","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1101\/gr.237362.118","volume":"28","author":"IX Wang","year":"2018","unstructured":"Wang, I. X. et al. Human proteins that interact with RNA\/DNA hybrids. Genome Res. 28, 1405\u20131414 (2018).","journal-title":"Genome Res"},{"key":"62309_CR66","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41586-023-05710-8","volume":"614","author":"J Nassour","year":"2023","unstructured":"Nassour, J. et al. Telomere-to-mitochondria signalling by ZBP1 mediates replicative crisis. Nature 614, 767\u2013773 (2023).","journal-title":"Nature"},{"key":"62309_CR67","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/2767-9764.CRC-23-0488","volume":"4","author":"KA Cottrell","year":"2024","unstructured":"Cottrell, K. A. et al. Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells. Cancer Res. Commun. 4, 986\u20131003 (2024).","journal-title":"Cancer Res. Commun."},{"key":"62309_CR68","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.celrep.2018.04.025","volume":"23","author":"A Cristini","year":"2018","unstructured":"Cristini, A., Groh, M., Kristiansen, M. S. & Gromak, N. RNA\/DNA Hybrid Interactome Identifies DXH9 as a Molecular Player in Transcriptional Termination and R-Loop-Associated DNA Damage. Cell Rep. 23, 1891\u20131905 (2018).","journal-title":"Cell Rep."},{"key":"62309_CR69","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.15252\/embj.201488726","volume":"33","author":"AK Mankan","year":"2014","unstructured":"Mankan, A. K. et al. Cytosolic RNA:DNA hybrids activate the cGAS \u2013STING axis. EMBO J. 33, 2937\u20132946 (2014).","journal-title":"EMBO J."},{"key":"62309_CR70","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/embj.201386117","volume":"33","author":"RE Rigby","year":"2014","unstructured":"Rigby, R. E. et al. RNA:DNA hybrids are a novel molecular pattern sensed by TLR9. EMBO J. 33, 542\u2013558 (2014).","journal-title":"EMBO J."},{"key":"62309_CR71","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1073\/pnas.1400075111","volume":"111","author":"SK Vanaja","year":"2014","unstructured":"Vanaja, S. K. et al. Bacterial RNA:DNA hybrids are activators of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. USA 111, 7765\u20137770 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62309_CR72","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nsmb.2662","volume":"20","author":"B Balk","year":"2013","unstructured":"Balk, B. et al. Telomeric RNA-DNA hybrids affect telomere-length dynamics and senescence. Nat. Struct. Mol. Biol. 20, 1199\u20131205 (2013).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"62309_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6220","volume":"5","author":"R Arora","year":"2014","unstructured":"Arora, R. et al. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells. Nat. Commun. 5, 5220 (2014).","journal-title":"Nat. Commun."},{"key":"62309_CR74","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.molcel.2024.11.025","volume":"85","author":"N Sasaki","year":"2025","unstructured":"Sasaki, N. et al. RNA sensing induced by chromosome missegregation augments anti-tumor immunity. Mol. Cell 85, 770\u2013786.e7 (2025).","journal-title":"Mol. Cell"},{"key":"62309_CR75","doi-asserted-by":"publisher","first-page":"103182","DOI":"10.1016\/j.dnarep.2021.103182","volume":"106","author":"D Castillo-Guzman","year":"2021","unstructured":"Castillo-Guzman, D. & Ch\u00e9din, F. Defining R-loop classes and their contributions to genome instability. DNA Repair 106, 103182 (2021).","journal-title":"DNA Repair"},{"key":"62309_CR76","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03538-8","volume":"594","author":"J Ouyang","year":"2021","unstructured":"Ouyang, J. et al. RNA transcripts stimulate homologous recombination by forming DR-loops. Nature 594, 283\u2013288 (2021).","journal-title":"Nature"},{"key":"62309_CR77","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41467-018-02894-w","volume":"9","author":"S Cohen","year":"2018","unstructured":"Cohen, S. et al. Senataxin resolves RNA: DNA hybrids forming at DNA double-strand breaks to prevent translocations. Nat. Commun. 9, 533\u2013533 (2018).","journal-title":"Nat. Commun."},{"key":"62309_CR78","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.molcel.2015.01.011","volume":"57","author":"E Hatchi","year":"2015","unstructured":"Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636\u2013647 (2015).","journal-title":"Mol. Cell"},{"key":"62309_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17858-2","volume":"11","author":"A Promonet","year":"2020","unstructured":"Promonet, A. et al. Topoisomerase 1 prevents replication stress at R-loop-enriched transcription termination sites. Nat. Commun. 11, 3940 (2020).","journal-title":"Nat. Commun."},{"key":"62309_CR80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nm.3043","volume":"19","author":"L Chen","year":"2013","unstructured":"Chen, L. et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 19, 209\u2013216 (2013).","journal-title":"Nat. Med."},{"key":"62309_CR81","doi-asserted-by":"publisher","first-page":"10370","DOI":"10.1093\/nar\/gkae700","volume":"52","author":"F van Gemert","year":"2024","unstructured":"van Gemert, F. et al. ADARp150 counteracts whole genome duplication. Nucleic Acids Res. 52, 10370\u201310384 (2024).","journal-title":"Nucleic Acids Res"},{"key":"62309_CR82","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41586-022-04896-7","volume":"607","author":"NW Hubbard","year":"2022","unstructured":"Hubbard, N. W. et al. ADAR1 mutation causes ZBP1-dependent immunopathology. Nature 607, 769\u2013775 (2022).","journal-title":"Nature"},{"key":"62309_CR83","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41586-022-04974-w","volume":"607","author":"R de Reuver","year":"2022","unstructured":"de Reuver, R. et al. ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation. Nature 607, 784\u2013789 (2022).","journal-title":"Nature"},{"key":"62309_CR84","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41586-022-04878-9","volume":"607","author":"H Jiao","year":"2022","unstructured":"Jiao, H. et al. ADAR1 averts fatal type I interferon induction by ZBP1. Nature 607, 776\u2013783 (2022).","journal-title":"Nature"},{"key":"62309_CR85","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1021\/acs.biochem.2c00686","volume":"62","author":"HG Mendoza","year":"2023","unstructured":"Mendoza, H. G., Matos, V. J., Park, S., Pham, K. M. & Beal, P. A. Selective inhibition of ADAR1 using 8-azanebularine-modified RNA duplexes. Biochemistry 62, 1376\u20131387 (2023).","journal-title":"Biochemistry"},{"key":"62309_CR86","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.1021\/jacs.3c13646","volume":"146","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Structurally specific Z-DNA proteolysis targeting chimera enables targeted degradation of adenosine deaminase acting on RNA 1. J. Am. Chem. Soc. 146, 7584\u20137593 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"62309_CR87","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s43018-025-00907-4","volume":"6","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Targeting ADAR1 with a small molecule for the treatment of prostate cancer. Nat. Cancer\u00a06, 474\u2013492 (2025).","journal-title":"Nat. Cancer"},{"key":"62309_CR88","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2767-9764.CRC-21-0027","volume":"1","author":"KA Cottrell","year":"2021","unstructured":"Cottrell, K. A., Torres, L. S., Dizon, M. G. & Weber, J. D. 8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR. Cancer Res. Commun. 1, 56\u201364 (2021).","journal-title":"Cancer Res. Commun."},{"key":"62309_CR89","doi-asserted-by":"crossref","unstructured":"Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., & Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dyn. Publ. Am. Assoc. Anat. 203, 253\u2013310 (1995).","DOI":"10.1002\/aja.1002030302"},{"key":"62309_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03917-2","volume":"9","author":"SJ Pettitt","year":"2018","unstructured":"Pettitt, S. J. et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat. Commun. 9, 1849 (2018).","journal-title":"Nat. Commun."},{"key":"62309_CR91","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. J. Eur. Soc. Med. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"62309_CR92","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinforma. Oxf. Engl. 34, i884\u2013i890 (2018).","journal-title":"Bioinforma. Oxf. Engl."},{"key":"62309_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. GigaScience 10, giab008 (2021).","journal-title":"GigaScience"},{"key":"62309_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"62309_CR95","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res"},{"key":"62309_CR96","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinforma. Oxf. Engl. 32, 2847\u20132849 (2016).","journal-title":"Bioinforma. Oxf. Engl."},{"key":"62309_CR97","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1002\/imt2.43","volume":"1","author":"Z Gu","year":"2022","unstructured":"Gu, Z. Complex heatmap visualization. iMeta 1, e43 (2022).","journal-title":"iMeta"},{"key":"62309_CR98","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ydbio.2017.05.025","volume":"428","author":"PT Kroeger","year":"2017","unstructured":"Kroeger, P. T. et al. The zebrafish kidney mutant zeppelin reveals that brca2\/fancd1 is essential for pronephros development. Dev. Biol. 428, 148\u2013163 (2017).","journal-title":"Dev. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62309-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:09:05Z","timestamp":1757322545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62309-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62309"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62309-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.M.C. makes the following disclosures: is named inventor on a patent describing the use of ADAR1 inhibitors as anti-cancer agents (WO\/2024\/189433). J.Z. makes the following disclosures: has received research funding and travel subsidies from Menarini. B.P. makes the following disclosures: has received research funding as part of an institutional program from: Astra Zeneca, Daiichi Sankyo, Gilead, Seagen, MSD; receives and\/or has received consulting fees from: Astra Zeneca (institutional), Seagen (institutional), Gilead (institutional), Novartis (institutional), Lilly (institutional), MSD (institutional), Pierre Fabre (personal), Daiichi Sankyo (institutional\/personal), Olema (institutional); has received travel subsidies from: Astra Zeneca; Pierre Fabre; MSD; Daiichi Sankyo, Pfizer. A.N.J.T. makes the following disclosures: Receipt of grants \/ research support: AstraZeneca research costs associated with OlympiA, Myriad Genetics research support for TNT Trial, Breast Cancer Now research grant to Institution, CRUK research grant to Institution. Receipt of honoraria or consultation fees: AstraZeneca, Inbiomotion, Gilead, Innovation in Breast Cancer Symposium, SABCS, GBCC, Cancer Panel, Research to Practise, AACR, Aicme, Penn Medicine, PAGE Therapeutics, Ellipses, VHIO, Dana Faber David Livingston Memorial Symposium, Tango Therapuetics, Guardant, CRUK, Neogenomics, Merck. Educational seminar: Guardant. Stock option: InBioMotion. Royalties: Benefits from ICR\u2019s Inventors Scheme associated with patents for use of several PARP inhibitors in DNA repair-deficient cancers held by AstraZeneca with royalty payments to A.N.J.T.\u2019s personal account and research accounts at the Institute of Cancer Research, and to the Institute of Cancer Research. Institutional financial interests: Royalties as above from AstraZeneca. Research costs from AstraZeneca, Myriad Genetics. Non-financial interests: Leadership\/Guideline Advisor roles: Director of Breast Cancer Now Research Centre\u2014ICR\/KCL, St Gallen Early Breast Cancer Guidelines Panel, ESMO Early Breast Cancer Guidelines Committee, ESMO Scientific Committee, Chair\u2014CRUK Clinical Research Committee, BCRF SAB member, Strategy Committee UK NCRI, Trustee The Cridlan Ross Smith Charitable Trust. C.J.L. makes the following disclosures: receives and\/or has received research funding from: AstraZeneca, Merck KGaA, Artios, Neophore; has received consultancy, SAB membership or honoraria payments from: FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures, Blacksmith Medicines, ForEx; has stock in: Tango, Ovibio, Hysplex, Tesselate, Ariceum. C.J.L. is also named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR \u201cRewards to Inventors\u201d scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid into C.J.L.\u2019s personal accounts and research accounts at the Institute of Cancer Research. C.J.L. is also named inventor on a patent describing the use of ADAR1 inhibitors as anti-cancer agents (WO 2024\/189433 A1). S.P.V. makes the following disclosures: has received research funding from Hoffman La Roche and AstraZeneca for unrelated research projects. As part of the Drug Development Department (DITEP), S.P.V. is principal investigator or sub-investigator of clinical trials from Abbvie, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Eli Lilly, Exelixis, Forma, Gamamabs, Genentech, Inc., GlaxoSmithKline, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharm. Dev., Inc., Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro Inc, and Xencor. S.P.V. has participated to advisory boards for Merck KGaA. S.P.V. is also named inventor on a patent describing the use of ADAR1 inhibitors as anti-cancer agents (WO 2024\/189433 A1). All other authors have no conflicts of interest or financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6972"}}